Skip to content

Study and comparison of the effects of ginger and cinnamon on chemotherapy-induced nausea and vomiting in patients with breast cancer

Study and comparison of the effects of ginger and cinnamon on chemotherapy-induced nausea and vomiting in patients with breast cancer

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210415050976N17
Enrollment
90
Registered
2026-03-15
Start date
2026-05-31
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Agranulocytosis secondary to cancer chemotherapy

Interventions

Intervention 1: Intervention Group 1: Patients in this group will receive capsules containing 250 mg of ginger (red-colored 250 mg ginger capsules, branded as Zintoma, manufactured by Gol Darou Compan

Sponsors

Jahrom University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Definitive diagnosis of cancer by an oncologist and a pathologist Receiving single-day chemotherapy courses with drugs having high potential for severe nausea, according to the guidelines of the American Society of Clinical Oncology Normal hematological and biochemical test results Informed consent for participation in the study

Exclusion criteria

Exclusion criteria: Simultaneous receipt of radiotherapy with chemotherapy Use of therapeutic doses of warfarin, heparin, or aspirin History of significant bleeding disorders (e.g., severe thrombocytopenia) Diagnosis of gastrointestinal tract cancer or inability to swallow History of ginger or cinnamon allergy, or consumption of these within the past weekPresence of conditions predisposing to nausea, such as uncontrolled hypertension, liver or renal failure, or gastrointestinal disorders Presence of conditions predisposing to nausea, such as uncontrolled hypertension, liver or renal failure, or gastrointestinal disorders Failure to take medications in three or more consecutive instances Use of other medications or therapies to reduce nausea (excluding standard antiemetic and antiemetic drugs prescribed in the study) Development of severe gastrointestinal complications during the study

Design outcomes

Primary

MeasureTime frame
Nausea-vomiting. Timepoint: Over three sessions (day 1, day 2, and day 3). Method of measurement: nausea and vomiting will be assessed using the INVR questionnaire (The Index of Nausea, Vomiting, and Retching).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Kalani

Jahrom University of Medical Sciences

k.navid@jums.ac.ir+98 71 5434 4002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026